

TABLE OF CONTENTS

ILLUSTRATIONS IN THIS BOOK	vi
PSAP-VII EDITORIAL BOARD.....	vii
WELCOME.....	viii
FACULTY POTENTIAL COI DISCLOSURE.....	ix
ROLE OF ACCP.....	ix
ROLE OF BPS.....	ix
CPE AND PROGRAM INSTRUCTIONS.....	x
POSTTEST INSTRUCTIONS.....	x

Oncology I.....	1
Oncology I Panel.....	3
Oncology I Subscriber Evaluation.....	5

CANCER SCREENING AND PREVENTION

By Kellie L. Jones, Pharm.D., BCOP

Introduction.....	7
Cancer Screening.....	7
Screening Guidelines.....	7
Screening Limitations.....	12
Chemoprevention.....	12
Breast Cancer.....	12
Colon Cancer.....	13
Prostate Cancer.....	13
Cervical Cancer.....	14
Ovarian Cancer.....	14
Antioxidant and Vitamin Supplementation.....	15
Impact of Cancer Screening and Prevention.....	16
Conclusion.....	16
Annotated Bibliography.....	17
Self-Assessment Questions.....	21

SUPPORTIVE CARE IN ONCOLOGY

**By Myke R. Green, Pharm.D., BCOP;
and Laura R. Bobolts, Pharm.D.**

Introduction.....	25
Gastrointestinal Toxicities.....	26
Chemotherapy-Induced Nausea and Vomiting.....	26
Constipation.....	27
Diarrhea.....	28
Cachexia.....	29
Hiccups.....	30
Calcium Homeostasis.....	31
Malignancy-Associated Hypercalcemia.....	31
Osteoporosis.....	33
Quality Patient Care.....	35
Conclusion.....	36
Annotated Bibliography.....	37
Self-Assessment Questions.....	41

NONMALIGNANT HEMATOLOGY

By Julianna A. Merten, Pharm.D., BCPS, BCOP

Introduction.....	47
Primary Immune Thrombocytopenia.....	47
Epidemiology, Nomenclature.....	47
Pathophysiology.....	48
Diagnosis.....	48
Treatment Goals.....	48
Quality Patient Care.....	49
Monitoring.....	54
Quality Improvement.....	54
Paroxysmal Nocturnal Hemoglobinuria.....	55
History, Epidemiology, Nomenclature.....	55
Pathophysiology.....	55
Diagnosis and Classification.....	55
Treatment Goals.....	56
Monitoring.....	59
Quality Improvement.....	59
Role of the Pharmacist.....	60
Conclusion.....	60
Annotated Bibliography.....	60
Self-Assessment Questions.....	65

Oncology II.....	69
Oncology II Panel.....	71
Oncology II Subscriber Evaluation.....	73

PANCREATIC ADENOCARCINOMAS AND ENDOCRINE CANCERS

**By Christy S. Harris, Pharm.D., BCPS, BCOP;
and Audrea H. Szabatura, Pharm.D., BCOP**

Pancreatic Adenocarcinoma.....	75
Risk Factors.....	75
Screening and Prevention.....	76
Diagnosis and Staging.....	76
Treatment.....	77
Supportive Care.....	80
Future Directions.....	81
Endocrine Tumors.....	81
Pancreatic Endocrine Tumors.....	82
Carcinoid Tumors.....	83
Role of the Pharmacist.....	84
Conclusion.....	85
Annotated Bibliography.....	85
Self-Assessment Questions.....	89

HEPATIC CANCER

By Sachin R. Shah, Pharm.D., FCCP, BCOP; and
Sarah M. Gressett Usery, Pharm.D., BCOP

Introduction	93
Hepatocellular Carcinoma	93
Risk Factors	93
Screening and Prevention	94
Diagnosis	94
Staging	94
Management	95
Hepatic Metastases	98
Epidemiology	98
Prognosis	98
Management	98
Role of the Pharmacist	101
Conclusion	101
Annotated Bibliography	101
Self-Assessment Questions	105

HEAD AND NECK CANCER

By Sarah L. Scarpace, Pharm.D., BCOP

Introduction	109
Pathogenesis and Risk Factors	109
Screening and Prevention	110
Clinical Presentation, Diagnosis, and Staging	110
Prognosis	110
Treatment	111
Goals	111
Treatment Modalities	111
Neoadjuvant Therapy	112
Chemoradiation	113
Treatment of Recurrent/Metastatic Disease	113
Clinical Trials	113
Supportive Care	113
Swallowing Difficulties and Drug Adherence	113
Malnutrition	114
Treatment-Induced Rash	114
Xerostomia	114
Mucositis	114
Role of ESAs	115
Role of the Pharmacist	115
Annotated bibliography.....	115
Self-Assessment Questions	119
Oncology III	123
Oncology III Panel.....	125
Oncology III Subscriber Evaluation.....	127

GYNECOLOGIC CANCERS

By Judith A. Smith, Pharm.D.,
FCCP, FISOPP, BCOP

Introduction	129
Endometrial Cancer	130
Etiology	131

Diagnosis	131
Treatment	131
Prevention	132
Cervical Cancer	134
Etiology	134
Screening	134
Diagnosis	134
Treatment	134
Prevention	135
Ovarian Cancer	135
Etiology	136
Diagnosis	136
Treatment	136
Quality Pharmaceutical Care	139
Chemotherapy	139
Supportive Care	140
Patient Education	140
Role of the Pharmacist	140
Conclusion	140
Annotated Bibliography.....	141
Self-Assessment Questions	145

NON-HODGKIN LYMPHOMA

By Viet Q. Ho, Pharm.D., BCOP

Introduction	149
Etiology	149
Pathophysiology	149
Classification	150
Clinical Presentation	150
Diagnosis and Prognosis	151
Staging	151
International Prognostic Index	151
Follicular Lymphoma International Prognostic Index	151
Response Criteria	152
Treatment	152
Indolent/Low-grade Lymphoma	152
Aggressive/Intermediate Grade Lymphoma	153
Highly Aggressive/High-grade Lymphoma	154
AIDS-Related B-Cell Lymphoma	154
Relapsed/Refractory Lymphoma	155
Adverse Effects	155
Neuropathy	156
Secondary Malignancies	156
Role of the Pharmacist	156
Conclusion	156
Annotated Bibliography	157
Self-Assessment Questions	161

UPDATES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

By Patrick J. Kiel, Pharm.D., BCPS, BCOP; and
Christopher A. Fausel, Pharm.D., BCPS, BCOP

Introduction	165
Transplantation Evaluation	166
Histocompatibility	166

Stem Cell Mobilization Strategies	167
Umbilical Cord Blood	168
Nonmyeloablative Regimens	168
Myeloablative Regimens	168
Autologous Hematopoietic Cell Transplantation	170
Multiple Myeloma	170
Non-Hodgkin and Hodgkin Lymphoma	170
Germ Cell Tumors	170
Allogeneic Hematopoietic Cell Transplantation	170
Acute Myeloid Leukemia	170
Chronic Myeloid Leukemia	170
Aplastic Anemia	170
Complications of HCT	171
Acute Graft-vs.-Host Disease	171
Chronic Graft-vs.-Host Disease	172
Sinusoidal Obstruction Syndrome	172
Idiopathic Pneumonia Syndrome	175
Late Complications	175
Role of the Pharmacist	175
Annotated Bibliography	176
Self-Assessment Questions	179
Reference Values for Common Laboratory Tests	182